Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags

Journal of Oncology Pharmacy Practice

Volumn 6, Issue 3, 2000, Pages 115-121

  Thiesen, Judith ^a   Krämer, Irene ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

infusion solution; injection concentrate; Irinotecan; photodegradation; physicochemical stability; PVC bag

Indexed keywords

EID: 84990359283     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/107815520000600305     Document Type: Article

References (17)

1. Hsiang Y-H, Liu LF, Wall ME, et al. DNA Topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989; 49: 4385-4389.
2. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989; 49: 1465-1469.
3. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989; 49: 5077-5082.
4. Tsao Y-P, Russo A, Nyamuswa G, Silber R, Liu LF. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 1993; 53: 5908-5914.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51: 4187-4191.
6. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs. 1995; 49: 11-19.
7. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci. 1992; 81: 676-684.
8. Akimoto K, Kawai A, Ohya K. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull. 1994; 42: 2135-2138.
9. Sasaki Y, Yoshida Y, Sudoh K, et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res. 1995; 86: 111-116.
10. Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J Pharm Sci. 1997; 86: 1410-1416.
11. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 1994; 54: 6330-6333.
12. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997; 33(4):245-259.
13. Campto® Technical Dossier. Aventis Pharma GmbH, Deutschland, September 1995.
14. Campto® Fachinformation. Aventis Pharma GmbH, Deutschland, August 1999.
15. Akimoto K, Kawai A, Ohya K, Sawada S, Aiyama R. Photodegradation reactions of CPT-11, a derivative of camptothecin: I. Chemical structure of main degradation products in aqueous solution. Drug Stability. 1996; 1: 118-122.
16. Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Pract. 1999; 5: 75-82.
17. Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of camptothecin: II. Photodegradation behaviour of CPT-11 in aqueous solution. Drug Stab. 1996; 1: 141-146.